F. Hoffmann-La Roche Ltd., Neuroscience & Rare Diseases (NRD) Research, Roche Innovation Center Basel, Basel, 4070, Switzerland.
HiQScreen Sàrl, 6 rte de Compois, Vésenaz, Geneva, 1222, Switzerland.
Curr Opin Pharmacol. 2021 Aug;59:3-10. doi: 10.1016/j.coph.2021.04.003. Epub 2021 May 18.
Ligand-gated ion channels are integral membrane proteins that activate through a change in conformation upon transmitter binding and were identified as key players of brain function. GABA receptors are major inhibitory ligand-gated ion channels of this protein family. They are the target of many therapeutic compounds widely used in the clinic and continue to attract the attention of academic and pharmaceutical laboratories. Advances in the knowledge of the structure of GABA receptors at the molecular level with unprecedented resolution enabled the determination of the binding sites of many allosteric modulators revealing the nature of their interactions with the receptors. Herein, we review the latest findings on allosteric modulation of GABA receptors and their relevance to drug discovery.
配体门控离子通道是整合膜蛋白,在递质结合后通过构象变化而激活,被鉴定为大脑功能的关键参与者。GABA 受体是该蛋白家族的主要抑制性配体门控离子通道。它们是许多临床广泛使用的治疗化合物的靶标,并且继续吸引学术和制药实验室的关注。在分子水平上对 GABA 受体结构的知识的进步以空前的分辨率确定了许多变构调节剂的结合位点,揭示了它们与受体相互作用的性质。在此,我们综述了 GABA 受体变构调节的最新发现及其与药物发现的相关性。